Indivior Pharmaceuticals (INDV) Notes Payables (2021 - 2023)

Indivior Pharmaceuticals' Notes Payables history runs 3 years deep, the most recent figure standing at $3.0 million for Q4 2023.

• On a quarterly basis, Notes Payables changed 0.0% year-over-year to $3.0 million in Q4 2023; TTM through Dec 2023 was $3.0 million, a 0.0% change from a year earlier, with the FY2023 full-year figure at $3.0 million, changed 0.0% from the prior year.
• Notes Payables was little changed at $3.0 million in Q4 2023 per INDV's latest filing, from $3.0 million in the prior quarter.
• Across five years, Notes Payables topped out at $3.0 million in Q4 2021 and bottomed at $3.0 million in Q4 2021.
• The 3-year median for Notes Payables is $3.0 million (2021), against an average of $3.0 million.
• Biggest YoY gain for Notes Payables was 0.0% in 2022; the steepest drop was 0.0% in 2022.
• Year by year, Notes Payables stood at $3.0 million in 2021, then changed by 0.0% to $3.0 million in 2022, then changed by 0.0% to $3.0 million in 2023.
• Per Business Quant, the three latest INDV Notes Payables figures stand at $3.0 million (Q4 2023), $3.0 million (Q4 2022), and $3.0 million (Q4 2021).